Follow-up study to evaluate sustained clearance rates of actinic keratoses up to one year after completion of studies GW01-0702, GW01-0703, GW01-0704, and GW01-0705.

Trial Profile

Follow-up study to evaluate sustained clearance rates of actinic keratoses up to one year after completion of studies GW01-0702, GW01-0703, GW01-0704, and GW01-0705.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2010

At a glance

  • Drugs Imiquimod (Primary)
  • Indications Actinic keratosis
  • Focus Therapeutic Use
  • Sponsors Graceway Pharmaceuticals
  • Most Recent Events

    • 29 Jan 2010 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
    • 29 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top